Journal article Open Access
Dr. Parul Mehta, Ms. Kajal Sharama, Anshu Patel*
Diabetes mellitus is a serious and spreading health issue that is a significant contributor to early death and chronic illness. It is a long-term metabolic condition defined by chronic insulin resistance and high blood glucose levels (hyperglycemia) brought on by insulin insufficiency. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is frequently prescribed to treat type 2 diabetes. Although Linagliptin has a low bioavailability (30%) due to its poor penetration profile and low water solubility. Furthermore, the requirement to maintain stable plasma concentrations for efficient long-term blood sugar control in diabetic patients supports the need for transdermal delivery of linagliptin. Transdermal matrix patches were created, and it was determined that the matrix kind of patches were suitable. The optimal formulation of the various matrix types (F1 to F6) was decided to be F5, which contains Eudragit RSPO and HPMC. It was also discovered that the drug permeation profile followed zero order kinetics. The patches were translucent, thin, and flexible. The current investigation revealed that Linagliptin matrix transdermal patches performed better in vitro than pure medication.
Key words: Diabetes mellitus, Linagliptin, Transdermal matrix patches, Formulation, Evaluation.